Literature DB >> 32789835

Provisional drug-coated balloon treatment guided by physiology on de novo coronary lesion.

Eun-Seok Shin1, Liew Houng Bang2, Eun Jung Jun3, Ae-Young Her4, Ju-Hyun Chung3, Scot Garg5, Joo Myung Lee6, Joon-Hyung Doh7, Chang-Wook Nam8, Bon-Kwon Koo9, Qiang Tang10.   

Abstract

Although drug-eluting stents (DES) have become the mainstay of percutaneous coronary intervention, late and very late stent thrombosis remains a concern. Drug-coated balloons (DCB) have the advantage of preserving the anti-restenotic benefits of DES while minimizing potential long-term safety concerns. Currently the two methods to ensure successful DCB treatment of a stenotic lesion are angiography or physiology-guided DCB application. This review will evaluate these two methods based on previous evidence and make suggestions on how to perform DCB treatment more efficiently and safely.

Entities:  

Keywords:  coronary artery disease; de novo lesion; diameter stenosis; drug-coated balloon; fractional flow reserve; physiology

Year:  2020        PMID： 32789835      PMCID： PMC8276995          DOI： 10.5603/CJ.a2020.0105

Source DB:  PubMed          Journal:  Cardiol J        ISSN： 1898-018X            Impact factor:   2.737


  33 in total

1.  Usefulness of fractional flow reserve to predict clinical outcome after balloon angioplasty.

Authors:  G J Bech; N H Pijls; B De Bruyne; K H Peels; H R Michels; H J Bonnier; J J Koolen
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

2.  Thrombus aspiration during ST-segment elevation myocardial infarction.

Authors:  Ole Fröbert; Bo Lagerqvist; Göran K Olivecrona; Elmir Omerovic; Thorarinn Gudnason; Michael Maeng; Mikael Aasa; Oskar Angerås; Fredrik Calais; Mikael Danielewicz; David Erlinge; Lars Hellsten; Ulf Jensen; Agneta C Johansson; Amra Kåregren; Johan Nilsson; Lotta Robertson; Lennart Sandhall; Iwar Sjögren; Ollie Ostlund; Jan Harnek; Stefan K James
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

3.  Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.

Authors:  Laura Mauri; Ajay J Kirtane; Stephan Windecker; Robert W Yeh; Harold L Dauerman; Matthew J Price; Thomas Christen; Dominic J Allocco; Ian T Meredith; Dean J Kereiakes
Journal:  Am Heart J       Date:  2018-08-17       Impact factor: 4.749

4.  Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.

Authors:  Elvin Kedhi; Azeem Latib; Alexandre Abizaid; David Kandzari; Ajay J Kirtane; Roxana Mehran; Matthew J Price; Daniel Simon; Stephen Worthley; Azfar Zaman; Sandeep Brar; Minglei Liu; Gregg W Stone; Stephan Windecker
Journal:  Am Heart J       Date:  2019-05-06       Impact factor: 4.749

5.  A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial.

Authors:  Fernando Alfonso; María Jose Pérez-Vizcayno; Alberto Cárdenas; Bruno García del Blanco; Arturo García-Touchard; José Ramón López-Minguéz; Amparo Benedicto; Mónica Masotti; Javier Zueco; Andrés Iñiguez; Maite Velázquez; Raúl Moreno; Vicente Mainar; Antonio Domínguez; Francisco Pomar; Rafael Melgares; Fernando Rivero; Pilar Jiménez-Quevedo; Nieves Gonzalo; Cristina Fernández; Carlos Macaya
Journal:  J Am Coll Cardiol       Date:  2015-07-07       Impact factor: 24.094

6.  Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions.

Authors:  Ju-Hyun Chung; Eun-Seok Shin; Ae-Young Her; Joo Myung Lee; Joon-Hyung Doh; Chang-Wook Nam; Bon-Kwon Koo
Journal:  Int J Cardiovasc Imaging       Date:  2019-10-09       Impact factor: 2.357

7.  Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Clemens von Birgelen; Liefke C van der Heijden; Mounir W Z Basalus; Marlies M Kok; Hanim Sen; Hans W Louwerenburg; K Gert van Houwelingen; Martin G Stoel; Frits H A F de Man; Gerard C M Linssen; Kenneth Tandjung; Carine J M Doggen; Job van der Palen; Marije M Löwik
Journal:  JAMA Cardiol       Date:  2017-03-01       Impact factor: 14.676

8.  Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.

Authors:  Jochen Wöhrle; Gerald S Werner
Journal:  Catheter Cardiovasc Interv       Date:  2012-11-08       Impact factor: 2.692

9.  Comparison of fractional flow reserve and angiographic characteristics after balloon angioplasty in de novo coronary lesions.

Authors:  Ju-Hyun Chung; Kyung Eun Lee; Ae-Young Her; Joo Myung Lee; Joon-Hyung Doh; Chang-Wook Nam; Bon-Kwon Koo; Eun-Seok Shin
Journal:  Int J Cardiovasc Imaging       Date:  2019-06-18       Impact factor: 2.357

10.  Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.

Authors:  Bernard De Bruyne; Nico H J Pijls; Bindu Kalesan; Emanuele Barbato; Pim A L Tonino; Zsolt Piroth; Nikola Jagic; Sven Möbius-Winkler; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith G Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Peter Jüni; William F Fearon
Journal:  N Engl J Med       Date:  2012-08-27       Impact factor: 91.245
View more
  1 in total

1.  Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions.

Authors:  Eun Jung Jun; Eun-Seok Shin; Eu-Vin Teoh; Youngjune Bhak; Song Lin Yuan; Chong-Mow Chu; Scot Garg; Houng Bang Liew
Journal:  Front Cardiovasc Med       Date:  2022-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.